Adovate Announces Patent Issuance in the United States for its Next Generation Adenosine 2B Receptor Antagonists
Patent covers lead drug candidate, ADO-5030, for asthma
Charlottesville, VA – November 15, 2023 – Adovate, LLC (“Adovate” or the “Company”), a pharmaceutical company developing novel drugs targeting adenosine receptors involved in major diseases, announces that the United States Patent and Trademark Office (USPTO) issued U.S. Patent Number 11,814,387, titled “Cyclic Amide-Containing Pyridyl Xanthines as A2B Antagonists” (the “Patent”).
The Patent covers novel compositions of matter (i.e., new molecular structures), including covering the Company’s lead molecule ADO-5030 for asthma and thousands of other novel molecules with similar structures. The Company believes additional lead candidates will be identified from the Patent and that those molecules may be advanced toward treating other diseases for which an adenosine 2B receptor (A2BR) antagonist could be a meaningful therapeutic. Due to important physiochemical properties of many of the molecules covered by the Patent, drug candidates derived from the Patent are expected to achieve effects promised by A2BR therapies, but with a therapeutic index heretofore unseen.
“This Patent represents a significant step in Adovate’s mission to confront some of the most challenging global health issues. Our innovative chemistry and approach not only paves the way for new therapies, but also exemplifies our commitment to making a substantial impact on public health,” said William Stilley, CEO of Adovate. “We believe our lead drug candidate has the potential to treat all forms of asthma with limited sides effects, making it a potential first-line therapy for asthma.”
About Asthma
Globally, asthma is a major disease affecting an estimated 262 million people and causing 455,000 deaths annually, according to the World Health Organization, and is the most common chronic disease amongst children (WHO 2023). The Centers for Disease Control and Prevention states that approximately 25 million people in the Unites States alone had asthma, equaling 8% of adults aged 18 and older and about 6.5% of children and adolescents (CDC 2021). Asthma is divided into two primary forms, eosinophilic asthma (EA) and non- eosinophilic asthma (NEA), based on the presence of eosinophils, a type of white blood cell, during the asthmatic response: EA is sometimes referred to as T-2 asthma due to its type 2 immunologic pathway response and NEA as low T-2/non-T-2 asthma. The Journal of Asthma and Allergy and the American Journal of Respiratory and Critical Care Medicine have reported that up to 30% (possibly more) of asthma patients have NEA and that NEA is associated with a poor response to inhaled glucocorticoids/steroids, which are first-line therapy for asthma (J Asthma Allergy. 2018; Am J Respir Crit Care Med 2018). Theophylline, a non-selective adenosine blocker, is approved for asthma of all forms and has demonstrated a response in both EA and NEA but has limited clinical utility due to its numerous and sometimes serious side-effects. It is hypothesized that that a selective adenosine 2B antagonist (A2BR) may be an effective and more tolerable treatment for both EA and NEA.
About Adovate, LLC
Adovate is a biopharmaceutical company focused on inventing and developing best-in-class drug candidates targeting the adenosine receptors. Additional information is available at www.adovate.com.
Forward Looking Statements
This communication contains certain “forward-looking statements” within the meaning of applicable securities laws. Such statements are based upon various facts and derived utilizing numerous important assumptions and are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Statements preceded by, followed by, or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. The forward-looking statements include statements regarding ADO-5030 being a new generation adenosine 2B receptor antagonist designed to transform asthma treatment, additional lead candidates being identified from the Patent, Patent molecules being advanced toward treating other diseases for which an adenosine 2B receptor (A2BR) antagonist could be a meaningful therapeutic, drug candidates being derived from the Patent achieving effects promised by A2BR therapies with a therapeutic index heretofore unseen, Adial’s commitment to making a substantial impact on public health, and ADO-5030 providing an additional and potentially more favorable option for current asthma treatments. Any forward-looking statements included herein reflect our current views, and they involve certain risks and uncertainties, including, among others, ADO-5030 developing into a novel therapeutic that could serve as a vital treatment option for the underserved patient population, Adovate’s ability to develop novel, patentable, next generation molecules targeting specific adenosine receptors which will create significant advancements in treatments for asthma and other diseases, ADO-5030 not having the liabilities of A2BR blockers such as theophylline, ADO-5030 bringing clinically meaningful benefit to asthma patients and potentially becoming the first-line therapy, and Adovate inventing and developing best-in-class drug candidates targeting adenosine receptors. These risks should not be construed as exhaustive. Any forward-looking statement speaks only as of the date on which it was initially made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise, unless required by law.
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations:
Media Relations: